D. Teplyuk, Aliya A. Kaisina, Shabnam Ibragimova, Af A Bestavashvili, I. O. Tinkova, E. Pashkova, J. Kaibullayeva, A. Nersesov, C. Pavlov
{"title":"Non-alcoholic fatty liver disease: from understanding risk factors to finding optimal treatment regimens: A review","authors":"D. Teplyuk, Aliya A. Kaisina, Shabnam Ibragimova, Af A Bestavashvili, I. O. Tinkova, E. Pashkova, J. Kaibullayeva, A. Nersesov, C. Pavlov","doi":"10.26442/20751753.2023.5.202272","DOIUrl":null,"url":null,"abstract":"Non-alcoholic fatty liver disease (NAFLD) is now a major risk factor for death among patients with liver disease. Currently, drugs that primarily affect surrogate markers of NAFLD are available. However, none of these drugs showed a significant effect on the course of steatohepatitis and fibrogenesis. The search for the most relevant lifestyle modification programs is still a priority in comprehensive treatment. A clinical case of follow-up of a comorbid patient is presented. Despite comprehensive treatment, disease regression was not achieved. NAFLD therapy remains a relevant issue. Finding new ways to affect the NAFLD course and individualize treatment approaches is necessary.","PeriodicalId":10550,"journal":{"name":"Consilium Medicum","volume":" ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2023-07-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Consilium Medicum","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.26442/20751753.2023.5.202272","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Non-alcoholic fatty liver disease (NAFLD) is now a major risk factor for death among patients with liver disease. Currently, drugs that primarily affect surrogate markers of NAFLD are available. However, none of these drugs showed a significant effect on the course of steatohepatitis and fibrogenesis. The search for the most relevant lifestyle modification programs is still a priority in comprehensive treatment. A clinical case of follow-up of a comorbid patient is presented. Despite comprehensive treatment, disease regression was not achieved. NAFLD therapy remains a relevant issue. Finding new ways to affect the NAFLD course and individualize treatment approaches is necessary.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
